Risk Factors for Low CD4+ Count Recovery Despite Viral Suppression among Participants Initiating Antiretroviral Treatment with CD4+ Counts > 500 cells/mm3: Findings from the Strategic Timing of AntiRetroviral Treatment (START) Trial.

Boatman, Jeffrey A; Baker, Jason V; Emery, Sean; Furrer, Hansjakob; Mushatt, David M; Sedlacek, Dalibor; Lundgren, Jens D; Neaton, James D (2019). Risk Factors for Low CD4+ Count Recovery Despite Viral Suppression among Participants Initiating Antiretroviral Treatment with CD4+ Counts > 500 cells/mm3: Findings from the Strategic Timing of AntiRetroviral Treatment (START) Trial. Journal of acquired immune deficiency syndromes JAIDS, 81(1), pp. 10-17. Wolters Kluwer Health 10.1097/QAI.0000000000001967

[img]
Preview
Text
00126334-900000000-96469.pdf - Accepted Version
Available under License Publisher holds Copyright.

Download (756kB) | Preview
[img] Text
Risk_Factors_for_Low_CD4__Count_Recovery_Despite.3.pdf - Published Version
Restricted to registered users only until 2 May 2020.
Available under License Publisher holds Copyright.

Download (331kB) | Request a copy

BACKGROUND Low CD4+ recovery among HIV-positive individuals who achieve virologic suppression is common but has not been studied among individuals initiating treatment at CD4+ counts > 500 cells/mm. SETTING United States, Africa, Asia, Europe & Israel, Australia, Latin America. METHODS Among immediate-ART participants in the Strategic Timing of AntiRetroviral Therapy trial, low CD4+ recovery was defined as a CD4+ increase < 50 cells/mm from baseline after 8 months despite viral load ≤ 200 copies/mL. Risk factors for low recovery were investigated with logistic regression. RESULTS 39.7% of participants had low CD4+ recovery. Male gender (OR 1.53, p = 0.007), lower screening CD4+ (OR 1.09 per 100 fewer cells/mm, p = 0.004), higher baseline CD8+ (OR 1.05 per 100 more cells/mm, p < 0.001), and lower HIV RNA (OR 1.93 per log10 decrease, p < 0.001) were associated with low CD4+ recovery. D-dimer had a quadratic association with low CD4+ recovery, with lowest odds occurring at 0.32 μg/mL. At lower HIV RNA levels, odds of low recovery were elevated across levels of screening CD4+ count, but at higher levels, odds of low CD4+ recovery were greater among those with lower versus higher screening CD4+. CONCLUSION Low CD4+ recovery is frequent among participants starting ART at high CD4+ counts. Risk factors include male gender, lower screening CD4+ cell counts, higher CD8+ cell counts, and lower HIV RNA levels. More follow-up is required to determine the impact of low CD4+ recovery on clinical outcomes.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Infectiology

UniBE Contributor:

Furrer, Hansjakob

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0894-9255

Publisher:

Wolters Kluwer Health

Language:

English

Submitter:

Annelies Luginbühl

Date Deposited:

25 Jun 2019 10:35

Last Modified:

24 Oct 2019 07:28

Publisher DOI:

10.1097/QAI.0000000000001967

PubMed ID:

30664075

BORIS DOI:

10.7892/boris.125454

URI:

https://boris.unibe.ch/id/eprint/125454

Actions (login required)

Edit item Edit item
Provide Feedback